pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
AbbVie Deutschland GmbH clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
AbbVie Deutschland GmbH projects
4 ClinicalTrials.gov programs sponsored by AbbVie Deutschland GmbH.
AbbVie Deutschland GmbH has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
ABBV-066, DEUCRAVACITINIB
AbbVie Deutschland GmbH & Co. KG
Plaque Psoriasis
1 trial -
Ibrutinib
AbbVie Deutschland GmbH & Co. KG
1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma
1 trial -
M24-528
AbbVie Deutschland GmbH & Co. KG
Neovascular age-related macular degeneration
1 trial -
M24-601
AbbVie Deutschland GmbH & Co. KG
Atopic Dermatitis
1 trial
Frequently asked questions
How many clinical projects does AbbVie Deutschland GmbH have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.